FibroBiologics (FBLG) Income Statement (2023 - 2026)
Income Statement report data from Mar 31, 2023 to Mar 31, 2026 for FibroBiologics (FBLG).
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Reported currency: USD
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Expenses | |||||||||||||
Research And Development | 2.95M (+268.75%) | 800K (-71.33%) | 2.79M (+36.76%) | 2.04M (+14.61%) | 1.78M (+30.88%) | 1.36M (+12.40%) | 1.21M (+23.47%) | 980K (+2.08%) | 960K (+24.68%) | 770K (+35.09%) | 570K (+3.64%) | 550K (+14.58%) | 480K |
Selling General And Administrative | 2.12M (+18.44%) | 1.79M (-20.44%) | 2.25M (-8.16%) | 2.45M (-10.91%) | 2.75M (+16.53%) | 2.36M (+10.28%) | 2.14M (-4.89%) | 2.25M (-9.64%) | 2.49M (+45.61%) | 1.71M (+15.54%) | 1.48M (-4.52%) | 1.55M (-13.41%) | 1.79M |
Operating Expenses | 5.07M (+95.75%) | 2.59M (-48.61%) | 5.04M (+12.25%) | 4.49M (-0.88%) | 4.53M (+22.10%) | 3.71M (+10.75%) | 3.35M (+4.04%) | 3.22M (-6.67%) | 3.45M (+39.11%) | 2.48M (+20.98%) | 2.05M (-1.91%) | 2.09M (-7.93%) | 2.27M |
Depreciation And Amortization | 70K (0.00%) | 70K (0.00%) | 70K (+16.67%) | 60K (+20.00%) | 50K (0.00%) | 50K (+25.00%) | 40K (0.00%) | 40K (0.00%) | 40K (+33.33%) | 30K (+200.00%) | 10K | - | - |
Operating Income | |||||||||||||
Operating Income | -5.07M (+95.75%) | -2.59M (-48.61%) | -5.04M (+12.25%) | -4.49M (-0.88%) | -4.53M (+22.10%) | -3.71M (+10.75%) | -3.35M (+4.04%) | -3.22M (-6.67%) | -3.45M (+39.11%) | -2.48M (+20.98%) | -2.05M (-1.91%) | -2.09M (-7.52%) | -2.26M |
Ebit | -5.07M (+95.75%) | -2.59M (-48.61%) | -5.04M (+12.25%) | -4.49M (-0.88%) | -4.53M (+22.10%) | -3.71M (+10.75%) | -3.35M (+4.04%) | -3.22M (-6.67%) | -3.45M (+39.11%) | -2.48M (+20.98%) | -2.05M (-1.91%) | -2.09M (-7.52%) | -2.26M |
EBITDA | -5.00M (+98.41%) | -2.52M (-49.30%) | -4.97M (+12.19%) | -4.43M (-1.12%) | -4.48M (+22.40%) | -3.66M (+10.57%) | -3.31M (+3.76%) | -3.19M (-6.45%) | -3.41M (+39.18%) | -2.45M (+20.10%) | -2.04M (-2.39%) | -2.09M (-7.52%) | -2.26M |
Other Income / Expenses | |||||||||||||
Interest Income | 20K (-33.33%) | 30K (-57.14%) | 70K (+40.00%) | 50K (-50.00%) | 100K (+66.67%) | 60K (-25.00%) | 80K (+14.29%) | 70K (+75.00%) | 40K | - | - | - | - |
Interest Expense | - | 200K | - | - | - | 10K (0.00%) | 10K (0.00%) | 10K | - | - | - | 10K (-92.86%) | 140K |
Net Interest Income | 20K (-33.33%) | 30K (-57.14%) | 70K (+40.00%) | 50K (-50.00%) | 100K (+42.86%) | 70K (-12.50%) | 80K (+14.29%) | 70K (+75.00%) | 40K | - | - | -10.00K (-92.31%) | -130.00K |
Other Non Operating Income | - | -620.00K | - | - | - | 30K | - | 30K | - | -210.00K (+50.00%) | -140.00K (+133.33%) | -60.00K (+500.00%) | -10.00K |
Net Income | |||||||||||||
Net Income From Continuing Operations | -5.00M (+54.32%) | -3.24M (-43.94%) | -5.78M (+24.03%) | -4.66M (-6.24%) | -4.97M (+60.32%) | -3.10M (+520.00%) | -500.00K | 900K | -8.46M (-12.96%) | -9.72M (+343.84%) | -2.19M (+1.39%) | -2.16M (-10.37%) | -2.41M |
Net Income | -5.00M (+54.32%) | -3.24M (-43.94%) | -5.78M (+24.03%) | -4.66M (-6.24%) | -4.97M (+60.32%) | -3.10M (+520.00%) | -500.00K | 900K | -8.46M (-12.96%) | -9.72M (+343.84%) | -2.19M (+1.39%) | -2.16M (-10.37%) | -2.41M |